Cargando…

Third Early “Booster” Dose Strategy in France of bnt162b2 SARS-CoV-2 Vaccine in Allogeneic Hematopoietic Stem Cell Transplant Recipients Enhances Neutralizing Antibody Responses

Immunocompromised individuals generally fail to mount efficacious immune humoral responses following vaccination. The emergence of SARS-CoV-2 variants of concern has raised the question as to whether levels of anti-spike protein antibodies achieved after two or three doses of the vaccine efficiently...

Descripción completa

Detalles Bibliográficos
Autores principales: Ahmed-Belkacem, Abdelhakim, Redjoul, Rabah, Brillet, Rozenn, Ahnou, Nazim, Leclerc, Mathieu, López-Molina, Dennis Salomón, Soulier, Alexandre, Gourgeon, Aurélie, Rodriguez, Christophe, Maury, Sébastien, Pawlotsky, Jean-Michel, Fourati, Slim
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9506309/
https://www.ncbi.nlm.nih.gov/pubmed/36146735
http://dx.doi.org/10.3390/v14091928
_version_ 1784796691140968448
author Ahmed-Belkacem, Abdelhakim
Redjoul, Rabah
Brillet, Rozenn
Ahnou, Nazim
Leclerc, Mathieu
López-Molina, Dennis Salomón
Soulier, Alexandre
Gourgeon, Aurélie
Rodriguez, Christophe
Maury, Sébastien
Pawlotsky, Jean-Michel
Fourati, Slim
author_facet Ahmed-Belkacem, Abdelhakim
Redjoul, Rabah
Brillet, Rozenn
Ahnou, Nazim
Leclerc, Mathieu
López-Molina, Dennis Salomón
Soulier, Alexandre
Gourgeon, Aurélie
Rodriguez, Christophe
Maury, Sébastien
Pawlotsky, Jean-Michel
Fourati, Slim
author_sort Ahmed-Belkacem, Abdelhakim
collection PubMed
description Immunocompromised individuals generally fail to mount efficacious immune humoral responses following vaccination. The emergence of SARS-CoV-2 variants of concern has raised the question as to whether levels of anti-spike protein antibodies achieved after two or three doses of the vaccine efficiently protect against breakthrough infection in the context of immune suppression. We used a fluorescence-based neutralization assay to test the sensitivity of SARS-CoV-2 variants (ancestral variant, Beta, Delta, and Omicron BA.1) to the neutralizing response induced by vaccination in highly immunosuppressed allogeneic HSCT recipients, tested after two and three doses of the BNT162b2 vaccine. We show that neutralizing antibody responses to the Beta and Delta variants in most immunocompromised HSCT recipients increased after three vaccine doses up to values similar to those observed in twice-vaccinated healthy adults and were significantly lower against Omicron BA.1. Overall, neutralization titers correlated with the amount of anti-S-RBD antibodies measured by means of enzyme immunoassay, indicating that commercially available assays can be used to quantify the anti-S-RBD antibody response as a reliable surrogate marker of humoral immune protection in both immunocompetent and immunocompromised individuals. Our findings support the recommendation of additional early vaccine doses as a booster of humoral neutralizing activity against emerging variants, in HSCT immunocompromised patients. In the context of Omicron circulation, it further emphasizes the need for reinforcement of preventive measures including the administration of monoclonal antibodies in this high-risk population.
format Online
Article
Text
id pubmed-9506309
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-95063092022-09-24 Third Early “Booster” Dose Strategy in France of bnt162b2 SARS-CoV-2 Vaccine in Allogeneic Hematopoietic Stem Cell Transplant Recipients Enhances Neutralizing Antibody Responses Ahmed-Belkacem, Abdelhakim Redjoul, Rabah Brillet, Rozenn Ahnou, Nazim Leclerc, Mathieu López-Molina, Dennis Salomón Soulier, Alexandre Gourgeon, Aurélie Rodriguez, Christophe Maury, Sébastien Pawlotsky, Jean-Michel Fourati, Slim Viruses Article Immunocompromised individuals generally fail to mount efficacious immune humoral responses following vaccination. The emergence of SARS-CoV-2 variants of concern has raised the question as to whether levels of anti-spike protein antibodies achieved after two or three doses of the vaccine efficiently protect against breakthrough infection in the context of immune suppression. We used a fluorescence-based neutralization assay to test the sensitivity of SARS-CoV-2 variants (ancestral variant, Beta, Delta, and Omicron BA.1) to the neutralizing response induced by vaccination in highly immunosuppressed allogeneic HSCT recipients, tested after two and three doses of the BNT162b2 vaccine. We show that neutralizing antibody responses to the Beta and Delta variants in most immunocompromised HSCT recipients increased after three vaccine doses up to values similar to those observed in twice-vaccinated healthy adults and were significantly lower against Omicron BA.1. Overall, neutralization titers correlated with the amount of anti-S-RBD antibodies measured by means of enzyme immunoassay, indicating that commercially available assays can be used to quantify the anti-S-RBD antibody response as a reliable surrogate marker of humoral immune protection in both immunocompetent and immunocompromised individuals. Our findings support the recommendation of additional early vaccine doses as a booster of humoral neutralizing activity against emerging variants, in HSCT immunocompromised patients. In the context of Omicron circulation, it further emphasizes the need for reinforcement of preventive measures including the administration of monoclonal antibodies in this high-risk population. MDPI 2022-08-30 /pmc/articles/PMC9506309/ /pubmed/36146735 http://dx.doi.org/10.3390/v14091928 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Ahmed-Belkacem, Abdelhakim
Redjoul, Rabah
Brillet, Rozenn
Ahnou, Nazim
Leclerc, Mathieu
López-Molina, Dennis Salomón
Soulier, Alexandre
Gourgeon, Aurélie
Rodriguez, Christophe
Maury, Sébastien
Pawlotsky, Jean-Michel
Fourati, Slim
Third Early “Booster” Dose Strategy in France of bnt162b2 SARS-CoV-2 Vaccine in Allogeneic Hematopoietic Stem Cell Transplant Recipients Enhances Neutralizing Antibody Responses
title Third Early “Booster” Dose Strategy in France of bnt162b2 SARS-CoV-2 Vaccine in Allogeneic Hematopoietic Stem Cell Transplant Recipients Enhances Neutralizing Antibody Responses
title_full Third Early “Booster” Dose Strategy in France of bnt162b2 SARS-CoV-2 Vaccine in Allogeneic Hematopoietic Stem Cell Transplant Recipients Enhances Neutralizing Antibody Responses
title_fullStr Third Early “Booster” Dose Strategy in France of bnt162b2 SARS-CoV-2 Vaccine in Allogeneic Hematopoietic Stem Cell Transplant Recipients Enhances Neutralizing Antibody Responses
title_full_unstemmed Third Early “Booster” Dose Strategy in France of bnt162b2 SARS-CoV-2 Vaccine in Allogeneic Hematopoietic Stem Cell Transplant Recipients Enhances Neutralizing Antibody Responses
title_short Third Early “Booster” Dose Strategy in France of bnt162b2 SARS-CoV-2 Vaccine in Allogeneic Hematopoietic Stem Cell Transplant Recipients Enhances Neutralizing Antibody Responses
title_sort third early “booster” dose strategy in france of bnt162b2 sars-cov-2 vaccine in allogeneic hematopoietic stem cell transplant recipients enhances neutralizing antibody responses
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9506309/
https://www.ncbi.nlm.nih.gov/pubmed/36146735
http://dx.doi.org/10.3390/v14091928
work_keys_str_mv AT ahmedbelkacemabdelhakim thirdearlyboosterdosestrategyinfranceofbnt162b2sarscov2vaccineinallogeneichematopoieticstemcelltransplantrecipientsenhancesneutralizingantibodyresponses
AT redjoulrabah thirdearlyboosterdosestrategyinfranceofbnt162b2sarscov2vaccineinallogeneichematopoieticstemcelltransplantrecipientsenhancesneutralizingantibodyresponses
AT brilletrozenn thirdearlyboosterdosestrategyinfranceofbnt162b2sarscov2vaccineinallogeneichematopoieticstemcelltransplantrecipientsenhancesneutralizingantibodyresponses
AT ahnounazim thirdearlyboosterdosestrategyinfranceofbnt162b2sarscov2vaccineinallogeneichematopoieticstemcelltransplantrecipientsenhancesneutralizingantibodyresponses
AT leclercmathieu thirdearlyboosterdosestrategyinfranceofbnt162b2sarscov2vaccineinallogeneichematopoieticstemcelltransplantrecipientsenhancesneutralizingantibodyresponses
AT lopezmolinadennissalomon thirdearlyboosterdosestrategyinfranceofbnt162b2sarscov2vaccineinallogeneichematopoieticstemcelltransplantrecipientsenhancesneutralizingantibodyresponses
AT soulieralexandre thirdearlyboosterdosestrategyinfranceofbnt162b2sarscov2vaccineinallogeneichematopoieticstemcelltransplantrecipientsenhancesneutralizingantibodyresponses
AT gourgeonaurelie thirdearlyboosterdosestrategyinfranceofbnt162b2sarscov2vaccineinallogeneichematopoieticstemcelltransplantrecipientsenhancesneutralizingantibodyresponses
AT rodriguezchristophe thirdearlyboosterdosestrategyinfranceofbnt162b2sarscov2vaccineinallogeneichematopoieticstemcelltransplantrecipientsenhancesneutralizingantibodyresponses
AT maurysebastien thirdearlyboosterdosestrategyinfranceofbnt162b2sarscov2vaccineinallogeneichematopoieticstemcelltransplantrecipientsenhancesneutralizingantibodyresponses
AT pawlotskyjeanmichel thirdearlyboosterdosestrategyinfranceofbnt162b2sarscov2vaccineinallogeneichematopoieticstemcelltransplantrecipientsenhancesneutralizingantibodyresponses
AT fouratislim thirdearlyboosterdosestrategyinfranceofbnt162b2sarscov2vaccineinallogeneichematopoieticstemcelltransplantrecipientsenhancesneutralizingantibodyresponses